BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Academic High Content Analysis: Applications in Basic and Translat
 ional Research
DTSTART:20130722T121500
DTEND:20130722T131500
DTSTAMP:20260407T041223Z
UID:a6a576ca73df2da259cd578955abc591f16c19e655d60c70248c47fc
CATEGORIES:Conferences - Seminars
DESCRIPTION:Justin D. Boyd\, Ph.D.\, Laboratory for Drug Discovery in Neur
 odegeneration\, Harvard Medical School\, Boston\, MA (USA)\nBio: Dr. Justi
 n D. Boyd is drug discovery scientist interested in developing high effici
 ency and high efficacy platforms for early and late stage drug discovery.
   Platforms include high performance computation for virtual screening an
 d molecular dynamics\; high content analysis for cell-based phenotypic scr
 eening\; and surrogate cellular assays for biomarker analysis for in vivo 
 drug efficacy.  He is a Co-Founder of PathDrugomics Inc\, Co-Founder and 
 Chair of the Board of the Chattanooga Research Institute (CRI)\, and is a 
 Leads Discovery Scientist in the Laboratory of Drug Discovery in Neurodege
 neration\, an affiliate lab of the Harvard NeuroDiscovery Center.  Prior 
 to his current positions\, Dr. Boyd worked at the National Institutes of H
 ealth as a visiting Scientist for Evotec\, a German pharmaceutical company
 \, and as a Postdoctoral Fellow in the Laboratory of Molecular Biology at 
 the National Institute for Neurological Disorders and Stroke.  Dr. Boyd h
 as a Ph.D. in Interdisciplinary Sciences with a specialty in Neuroscience 
 from the University of Tennessee Health Science Center and a Bachelor of S
 cience in Biology from Rhodes College.\nAs CRI’s Co-Founder and Chair of
  the Board\, Dr. Boyd is responsible for the launch of CRI’s platform de
 velopments through academic and business partnerships.  At Harvard\, Dr. 
 Boyd directs the High Content Imaging and Analysis program and is developi
 ng ex vivo biomarker analytical assays to monitor drug efficacy.  Dr. Boy
 d is also a technology consultant for the biotech and pharmaceutical indus
 tries across the country.\nDr. Boyd has fifteen years experience in resear
 ch in neuroscience\, stem cell research and drug discovery.  He is publis
 hed in the fields of neurobiology\, stem cell biology\, infectious disease
  and drug discovery\, reflecting his strong experience in interdisciplinar
 y approaches to research.\nBIOENGINEERING SANDWICH SEMINAR\nThe current dr
 ug discovery environment requires academic institutions to deliver more ad
 vanced programs into the pipeline. The Laboratory of Drug Discovery in Neu
 rodegeneration\, a Harvard NeuroDiscovery Center Lab \, facilitates in acc
 elerating academic drug discovery by providing resources to the basic rese
 archers within the Harvard and greater Boston area that enable drug discov
 ery activities from screening to lead optimization. The latest and fastest
  growing platform within LDDN is the High Content Platform\, an automated 
 imaging and image analysis platform. Image based assays provide a richer i
 nsight into the decision making process of compound screening. It also pro
 vides a means to mine data for multiple phenotypic fingerprints. Dr. Boyd 
 will present an overview of the LDDN and how it deploys high content analy
 sis in academic basic and translational research.
LOCATION:SV1717a http://map.epfl.ch/?room=sv1717a
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR